Halyard Health, Inc. (NYSE:HYH) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

Several other equities analysts have also commented on the company. Zacks Investment Research raised Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research report on Wednesday, July 12th. BidaskClub lowered Halyard Health from a “buy” rating to a “hold” rating in a research report on Saturday, July 8th. Deutsche Bank AG lifted their price target on Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. KeyCorp reaffirmed a “hold” rating on shares of Halyard Health in a research report on Tuesday, October 17th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $45.00 price target on shares of Halyard Health in a research report on Thursday, September 21st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $44.00.

Shares of Halyard Health (NYSE HYH) traded up $0.33 during trading on Friday, reaching $47.33. The company’s stock had a trading volume of 509,701 shares, compared to its average volume of 391,256. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.13 and a quick ratio of 1.11. The stock has a market capitalization of $2,220.00, a price-to-earnings ratio of 22.49, a P/E/G ratio of 3.14 and a beta of 1.69. Halyard Health has a fifty-two week low of $32.60 and a fifty-two week high of $50.99.

Halyard Health (NYSE:HYH) last announced its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, beating the consensus estimate of $0.47 by $0.13. The business had revenue of $401.40 million during the quarter, compared to analyst estimates of $394.54 million. Halyard Health had a return on equity of 8.65% and a net margin of 3.52%. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.48 earnings per share. equities analysts expect that Halyard Health will post 2.08 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/04/halyard-health-inc-hyh-upgraded-to-buy-at-valuengine.html.

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. raised its position in shares of Halyard Health by 6,362.1% in the 1st quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock worth $226,229,000 after purchasing an additional 5,847,442 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Halyard Health by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock worth $165,711,000 after purchasing an additional 196,367 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Halyard Health by 19.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,133,049 shares of the medical instruments supplier’s stock worth $123,067,000 after purchasing an additional 507,893 shares during the last quarter. Goldman Sachs Group Inc. raised its position in shares of Halyard Health by 242.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,864,646 shares of the medical instruments supplier’s stock worth $73,244,000 after purchasing an additional 1,320,735 shares during the last quarter. Finally, State Street Corp raised its position in shares of Halyard Health by 7.5% in the 2nd quarter. State Street Corp now owns 1,702,423 shares of the medical instruments supplier’s stock worth $66,872,000 after purchasing an additional 119,154 shares during the last quarter. 91.03% of the stock is owned by hedge funds and other institutional investors.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.